BJDX (Bluejay Diagnostics) Current Accrued Expense: $1.28 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJDX Bluejay Diagnostics Inc BJDX
22 GF Score
Price $0.84
! 1 Warning Sign
View Full Analysis

What is Bluejay Diagnostics Current Accrued Expense?

Bluejay Diagnostics BJDX +0.19% 22 Current Accrued Expense is $1.28 Mil as of Jun. 2026. GuruFocus rates BJDX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Bluejay Diagnostics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $1.28 Mil.

Bluejay Diagnostics's quarterly Current Accrued Expense increased from Dec. 2025 ($0.81 Mil) to Mar. 2026 ($0.84 Mil) and increased from Mar. 2026 ($0.84 Mil) to Jun. 2026 ($1.28 Mil).

Bluejay Diagnostics's annual Current Accrued Expense declined from Dec. 2023 ($1.12 Mil) to Dec. 2024 ($0.55 Mil) but then increased from Dec. 2024 ($0.55 Mil) to Dec. 2025 ($0.81 Mil).

Bluejay Diagnostics Current Accrued Expense Related Terms

Bluejay Diagnostics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Bluejay Diagnostics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bluejay Diagnostics Current Accrued Expense Chart

Bluejay Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 0.34 0.84 1.12 0.55 0.81

Bluejay Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.82 0.81 0.84 1.28
BJDX
22GF Score
Bluejay Diagnostics Inc BJDX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bluejay Diagnostics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.28 Mil mean?
Bluejay Diagnostics (BJDX) has a Current Accrued Expense of $1.28 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Bluejay Diagnostics and its competitors.
Is Bluejay Diagnostics' Current Accrued Expense too high?
Bluejay Diagnostics' current Current Accrued Expense is $1.28 Mil. Overall, Bluejay Diagnostics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' Current Accrued Expense compare to ODYY and VTAK?
Bluejay Diagnostics' Current Accrued Expense of $1.28 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Bluejay Diagnostics and its competitors. Bluejay Diagnostics's current Current Accrued Expense is $1.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current Current Accrued Expense of $1.28 Mil. The current Current Accrued Expense is $1.28 Mil. Bluejay Diagnostics' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current Current Accrued Expense is $1.28 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bluejay Diagnostics Business Description

Address 360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
22GF Score

Get the complete analysis for BJDX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.84
Price